This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Opinion: Reviewing the current clinical landscape for wet-AMD and the potential of Roche's Susvimo

Ticker(s): RHHBY, REGN

Who's the expert?

Institution: Hawaii Vision Specialist

  • Board-certified ophthalmologist since 1999 and founded Capital Vision
  • Manages 300 patients with GA
  • Clinical interests include cataract surgery, ocular trauma, glaucoma treatment and surgery, corneal diseases and surgeries , pterygium surgeries, retinal lasers and intravitreal injections

Interview Goal
.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.